• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·GKB.BO
Share

GKB Ophthalmics Limited Stocks

₹ 57Last Updated 29.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

₹ 3.00M

₹ 57
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

GKB Ophthalmics Ltd. operates as a holding company, primarily engaged in the production and distribution of ophthalmic lenses crafted from both glass and plastic. The firm's comprehensive product portfolio encompasses mineral, finished, semi-finished, and organic lenses, alongside various glass and bifocal molds. Its business activities span both the Indian domestic market and international regions. Founded by Krishna Gopal Gupta on December 10, 1981, the company maintains its corporate headquarters in Mapusa, India.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 22:48

SpaceX has been awarded a $1.6 billion contract by the U.S. Space Force

30.07.2026 22:43

"AI-Nostradamus" sold part of its portfolio due to losses from the tech stock crash

30.07.2026 21:41

Amazon's AI spending has spiraled out of control, and the company is now trying to rein it in — FT

30.07.2026 21:41

Adidas shares plummeted at a record pace. What does the World Cup have to do with this?

30.07.2026 21:00

"Protection Against AI on Wall Street": What the Market Expects from Apple's Report

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026